



April 30, 2018

To
National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India

To
BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001,
Maharashtra, India

Dear Sir/Madam,

Sub : **Intimation regarding execution of Share Purchase Agreement, with respect to the investment in International Stemcell Services Limited.**

Ref : **Regulation 30 (3) and (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Scrip Code : **NSE Scrip Code: HCG; BSE Scrip Code: 539787**

This is to inform you that, HealthCare Global Enterprises Limited (“the Company”), has entered into a Share Purchase Agreement (“SPA”) for the purchase of equity shares of International Stemcell Services Limited (“ISSL” or “iCrest”) to an extent of 12.00% (Twelve Percent) from the existing shareholders of ISSL.

Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015, dated September 09, 2015, to be provided with respect to execution of Share Purchase Agreement:

Share Purchase Agreement:

(a) Name of the target entity, details in brief such as size etc.;

ISSL is a public limited company incorporated under the Companies Act, 1956, that carries out research activities with respect to stem cells and regenerative medicine, at Bangalore, Karnataka.

(b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;

The acquisition of shares does not fall within related party transaction; and none of the promoter/ promoter group/ group companies of the Company have any interest in ISSL.

(c) Industry to which the entity being acquired belongs;

ISSL is a provider of healthcare services.

(d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



Both the Company and ISSL are providers of healthcare services.

ISSL is a knowledge-centric company in the space of stem cells and regenerative medicine. The developments in healthcare of late have established value of regenerative medicine, offering new found hope to patients. There is synergy with Company in using adult stem cells in treating several conditions including cancer.

The research activities with respect to stem cells and regenerative medicine carried out by ISSL would support the Company in the development of targeted therapies for cancer treatment.

(e) Brief details of any governmental or regulatory approvals required for the acquisition;

The acquisition of shares would not require any government or regulatory approvals.

(f) Indicative time period for completion of the acquisition;

The acquisition of shares has been completed as on date.

(g) Nature of consideration - whether cash consideration or share swap and details of the same;

The consideration for the acquisition of shares is in the form of cash.

(h) Cost of acquisition or the price at which the shares are acquired;

The Company has acquired 10,860 equity shares of ISSL for INR 56,07,670 (Indian Rupees Fifty-Six Lakh Seven Thousand Six Hundred and Seventy Only) from the existing shareholders of ISSL.

(i) percentage of shareholding / control acquired and / or number of shares acquired;

The Company would hold 12% of the outstanding share capital in ISSL.

(j) brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, country in which the acquired entity has presence and any other significant information (in brief);

ISSL was incorporated on 17th September, 2008, in Karnataka, India, for carrying out research activities with respect to stem cells and regenerative medicine in Bangalore.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,
For HealthCare Global Enterprises Limited

SUNU MANUEL Digitally signed by SUNU
MANUEL
Date: 2018.04.30 19:26:00 +05'30'

Sunu Manuel
Company Secretary & Compliance Officer

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



April 30, 2018

To
National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India

To
BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001,
Maharashtra, India

Dear Sir/Madam,

Sub : Intimation regarding execution of Share Purchase Agreement, with respect to the investment in International Stemcell Services Limited.

Ref : Regulation 30 (3) and (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Scrip Code : NSE Scrip Code: HCG; BSE Scrip Code: 539787

This is to inform you that, HealthCare Global Enterprises Limited (“the Company”), has entered into a Share Purchase Agreement (“SPA”) for the purchase of equity shares of International Stemcell Services Limited (“ISSL” or “iCrest”) to an extent of 12.00% (Twelve Percent) from the existing shareholders of ISSL.

Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015, dated September 09, 2015, to be provided with respect to execution of Share Purchase Agreement:

Share Purchase Agreement:

(a) *Name of the target entity, details in brief such as size etc.;*

ISSL is a public limited company incorporated under the Companies Act, 1956, that carries out research activities with respect to stem cells and regenerative medicine, at Bangalore, Karnataka.

(b) *Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;*

The acquisition of shares does not fall within related party transaction; and none of the promoter/ promoter group/ group companies of the Company have any interest in ISSL.

(c) *Industry to which the entity being acquired belongs;*

ISSL is a provider of healthcare services.

(d) *Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);*



HealthCare Global Enterprises Ltd.

HCG Tower #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027.

91 80 3366 9999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



The Specialist
in Cancer Care

adding life to years

Both the Company and ISSL are providers of healthcare services.

ISSL is a knowledge-centric company in the space of stem cells and regenerative medicine. The developments in healthcare of late have established value of regenerative medicine, offering new found hope to patients. There is synergy with Company in using adult stem cells in treating several conditions including cancer.

The research activities with respect to stem cells and regenerative medicine carried out by ISSL would support the Company in the development of targeted therapies for cancer treatment.

(e) *Brief details of any governmental or regulatory approvals required for the acquisition;*

The acquisition of shares would not require any government or regulatory approvals.

(f) *Indicative time period for completion of the acquisition;*

The acquisition of shares has been completed as on date.

(g) *Nature of consideration - whether cash consideration or share swap and details of the same;*

The consideration for the acquisition of shares is in the form of cash.

(h) *Cost of acquisition or the price at which the shares are acquired;*

The Company has acquired 10,860 equity shares of ISSL for INR 56,07,670 (Indian Rupees Fifty-Six Lakh Seven Thousand Six Hundred and Seventy Only) from the existing shareholders of ISSL.

(i) *percentage of shareholding / control acquired and / or number of shares acquired;*

The Company would hold 12% of the outstanding share capital in ISSL.

(j) *brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, country in which the acquired entity has presence and any other significant information (in brief);*

ISSL was incorporated on 17th September, 2008, in Karnataka, India, for carrying out research activities with respect to stem cells and regenerative medicine in Bangalore.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer



HealthCare Global Enterprises Ltd.

HCG Tower #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027.

91 80 3366 9999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489